Fangzheng Cao

Mr. Fangzheng Cao


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 April 2024 in Heliyon
Verified
Journal Article
Open access
PJP Jiang
P Jiang
HZHouwen Zhang
Houwen Zhang
XWXu Wang
Xu Wang
FCFangzheng Cao
Fangzheng Cao
CLChunrong Li
Chunrong Li
Cerebral hyperperfusion syndrome (CHS) is the most severe complication of carotid artery stenting (CAS) or endarterectomy (CEA). Staging treatment can effectively reduce the risk of CHS without increasing the risk of ischemic stroke. The first stage of balloon dilatation is critical for staged treatment. However, the successful criterion of the first stage balloon dilatation is still inconsistent. In the current study presents a case of a 61-year-old male with bilateral internal carotid subtotal occlusion, transcranial doppler (TCD) was used to measure middle cerebral artery (MCA) flow rate on the narrow side of surgery and the results are promising. Intraoperative TCD monitoring is expected to be an evaluation criterion for staged angioplasty for carotid artery stenosis. The approach of blood flow velocity in the brain based on intraoperative measurement of TCD during the treatment of this patient is a new idea for staging treatment in the future.

2 September 2025 in Brain and Behavior
Verified
Journal Article
Open access
HZHouwen Zhang
Houwen Zhang
CLChunrong Li
Chunrong Li
JYJialin Yu
Jialin Yu
YLYu Liang
Yu Liang
YWYou Wu
You Wu
FCFangzheng Cao
Fangzheng Cao
Background: Parkinson's disease (PD) is a progressive neurodegenerative condition characterized by motor impairments and intricate pathophysiological mechanisms. Although cerebrospinal fluid (CSF) metabolites are viewed as potential biomarkers, the primarily observational design of the majority of existing studies limits the ability to draw causal conclusions. Objective: The purpose of this research was to explore the causal link between CSF metabolites and PD by employing two‐sample Mendelian randomization (TSMR). Methods: Data on CSF metabolites were acquired from the two longitudinal cohort studies. Information regarding PD was gathered from the International Parkinson's Disease Genomics Consortium. Instrumental variables (IVs) for 338 CSF metabolites were identified based on notable SNPs. Causal impacts were assessed using Mendelian randomization techniques including inverse variance weighted (IVW) analysis and MR‐Egger regression. The analyses included sensitivity assessments to evaluate issues related to heterogeneity and pleiotropy. Results: Significant causal associations were found between several CSF metabolites and PD. Higher levels of glycerophosphoinositol, sphingomyelin, and oxalate were linked to increased PD risk, while elevated caffeine levels appeared protective. After FDR correction, glycerophosphoinositol, oxalate, and caffeine remained significant. Sensitivity analyses confirmed robustness with no heterogeneity or pleiotropy. Conclusion: This analysis of MR reveals multiple CSF metabolites that have causal links to PD. Increased levels of glycerophosphoinositol and oxalate are associated with higher risk, whereas caffeine provide protective benefits. These metabolites may act as potential biomarkers and treatment targets for PD.